Effects of antipsychotic drugs on the expression of synaptic proteins and dendritic outgrowth in hippocampal neuronal cultures

Synapse

Volumn 67, Issue 5, 2013, Pages 224-234

  Park, Sung Woo ^a   Lee, Chan Hong ^a   Cho, Hye Yeon ^a   Seo, Mi Kyoung ^a   Lee, Jung Goo ^a,b   Lee, Bong Ju ^a,b   Seol, Wongi ^c   Kee, Baik Seok ^d   Kim, Young Hoon ^a,b  

^a Inje University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

Atypical antipsychotics; Hippocampal dendritic outgrowth; Synaptic proteins

Indexed keywords

ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; POSTSYNAPTIC DENSITY PROTEIN 95; QUETIAPINE; SYNAPTOPHYSIN; ZIPRASIDONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; DRUG MECHANISM; FETUS; HIPPOCAMPUS; NERVE CELL CULTURE; NERVE CELL GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; DENDRITES; GENE EXPRESSION; HIPPOCAMPUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOPHYSIN; UP-REGULATION;

EID: 84875551571     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21634     Document Type: Article

References (55)

1. Abbas AI, Yadav PN, Yao WD, Arbuckle MI, Grant SG, Caron MG, Roth BL. 2009. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci 29:7124-7136.
2. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM. 2003. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 71:127-131.
3. Bastianetto S, Danik M, Mennicken F, Williams S, Quirion R. 2006. Prototypical antipsychotic drugs protect hippocampal neuronal cultures against cell death induced by growth medium deprivation. BMC Neurosci 7:28.
4. Bragina L, Melone M, Fattorini G, Torres-Ramos M, Vallejo-Illarramendi A, Matute C, Conti F. 2006. GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation. J Neurochem 99:134-141.
5. Chambers JS, Thomas D, Saland L, Neve RL, Perrone-Bizzozero NI. 2005. Growth-associated protein 43 (GAP-43) and synaptophysin alterations in the dentate gyrus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:283-290.
6. Critchlow HM, Maycox PR, Skepper JN, Krylova O. 2006. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci 32:356-365.
7. Daly C, Sugimori M, Moreira JE, Ziff EB, Llinás R. 2000. Synaptophysin regulates clathrin-independent endocytosis of synaptic vesicles. Proc Natl Acad Sci USA 97:6120-6125.
8. de Bartolomeis A, Aloj L, Ambesi-Impiombato A, Bravi D, Caracò C, Muscettola G, Barone P. 2002. Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Brain Res Mol Brain Res 98:124-129.
9. Delotterie D, Ruiz G, Brocard J, Schweitzer A, Roucard C, Roche Y, Suaud-Chagny MF, Bressand K, Andrieux A. 2010. Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology (Berl) 208:131-141.
10. Durany N, Thome J. 2004. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psychiatry 19:326-337.
11. Eastwood SL, Harrison PJ. 2005. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 7:159-172.
12. Eastwood SL, Heffernan J, Harrison PJ. 1997. Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticity-associated genes. Mol Psychiatry 2:322-329.
13. Eastwood SL, Cotter D, Harrison PJ. 2001. Cerebellar synaptic protein expression in schizophrenia. Neuroscience 105:219-229.
14. Ehrlich I, Klein M, Rumpel S, Malinow R. 2007. PSD-95 is required for activity-driven synapse stabilization. Proc Natl Acad Sci USA 104:4176-4181.
15. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. 2000. PSD-95 involvement in maturation of excitatory synapses. Science 290:1364-1368.
16. Elmariah SB, Crumling MA, Parsons TD, Balice-Gordon RJ. 2004. Postsynaptic TrkB-mediated signaling modulates excitatory and inhibitory neurotransmitter receptor clustering at hippocampal synapses. J Neurosci 24:2380-2393.
17. Gisabella B, Bolshakov VY, Benes FM. 2005. Regulation of synaptic plasticity in a schizophrenia model. Proc Natl Acad Sci USA 102:13301-13306.
18. Hammonds MD, Shim SS. 2009. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105:113-119.
19. Han K, Kim E. 2008. Synaptic adhesion molecules and PSD-95. Prog Neurobiol 84:263-283.
20. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA. 2005. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25:372-383.
21. Huang ZJ, Kirkwood A, Pizzorusso T, Porciatti V, Morales B, Bear MF, Maffei L, Tonegawa S. 1999. BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex. Cell 98:739-755.
22. Iasevoli F, Tomasetti C, Marmo F, Bravi D, Arnt J, de Bartolomeis A. 2010. Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology (Berl) 212:329-344.
23. Ji Y, Pang PT, Feng L, Lu B. 2005. Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci 8:164-172.
24. Kaech S, Banker G. 2006. Culturing hippocampal neurons. Nat Protoc 1:2406-2415.
25. Karson CN, Mrak RE, Schluterman KO, Sturner WQ, Sheng JG, Griffin WS. 1999. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'. Mol Psychiatry 4:39-45.
26. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators; Neurocognitive Working Group. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64:633-647.
27. Kim NR, Park SW, Lee JG, Kim YH. 2008. Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells. Prog Neuropsychopharmacol Biol Psychiatry 32:633-642.
28. Kinon BJ, Lieberman JA. 1996. Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology (Berl) 124:2-34.
29. Klimaschewski L, Nindl W, Pimpl M, Waltinger P, Pfaller K. 2002. Biolistictransfection and morphological analysis of cultured sympathetic neurons. J Neurosci Methods 15:63-71.
30. Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A. 2002. Postsynaptic induction of BDNFmediated long-term potentiation. Science 295:1729-1734.
31. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. 2005. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25:11288-11299.
32. Lessmann V, Gottmann K, Malcangio M. 2003. Neurotrophin secretion: current facts and future prospects. Prog Neurobiol 69:341-374.
33. Lu XH, Dwyer DS. 2005. Second-generation antipsychotic drugs, olanzapine quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 27:43-64.
34. Manschreck TC, Boshes RA. 2007. The CATIE schizophrenia trial: Results, impact, controversy. Harv Rev Psychiatry 15:245-258.
35. Mendrek A, Kiehl KA, Smith AM, Irwin D, Forster BB, Liddle PF. 2005. Dysfunction of a distributed neural circuitry in schizophrenia patients during a working-memory performance. Psychol Med 35:187-196.
36. Nasrallah HA. 2006. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 11:32-39.
37. Newcomer JW. 2007. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry 68:20-27.
38. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL, Lu B. 2004. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306:487-491.
39. Parikh V, Khan MM, Mahadik SP. 2004. Olanzapine counteracts reduction of brain derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett 356:135-139.
40. Park SW, Lee SK, Kim JM, Yoon JS, Kim YH. 2006. Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett 402:25-29.
41. Park SW, Lee CH, Lee JG, Lee SJ, Kim NR, Choi SM, Kim YH. 2009a. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA expression in the hippocampus and neocortex of rats. J Psychiatr Res 43:274-281.
42. Park SW, Lee JG, Ha EK, Choi SM, Cho HY, Seo MK, Kim YH. 2009b. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 19:356-362.
43. Poo MM. 2001. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2:24-32.
44. Prange O, Wong TP, Gerrow K, Wang YT, El-Husseini A. 2004. A balance between excitatory and inhibitory synapses is controlled by PSD-95 and neuroligin. Proc Natl Acad Sci USA 101:13915-13920.
45. Shen K, Cowan CW. 2010. Guidance molecules in synapse formation and plasticity. Cold Spring Harb Perspect Biol 2:1-18.
46. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. 1997. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933-944.
47. Tarsa L, Goda Y. 2002. Synaptophysin regulates activity-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci USA 99:1012-1016.
48. Toro C, Deakin JF. 2005. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80:323-330.
49. Tyler WJ, Pozzo-Miller L. 2003. Miniature synaptic transmission and BDNF modulate dendritic spine growth and form in rat CA1 neurones. J Physiol 553:497-509.
50. Valtorta F, Pennuto M, Bonanomi D, Benfenati F. 2004. Synaptophysin: Leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 26:445-453.
51. Vawter MP, Howard AL, Hyde TM, Kleinman JE, Freed WJ. 1999. Alterations of hippocampal secreted N-CAM in bipolar disorder and synaptophysin in schizophrenia. Mol Psychiatry 4:467-475.
52. Yang PC, Yang CH, Huang CC, Hsu KS. 2008. Phosphatidylinositol 3-kinase activation is required for stress protocol-induced modification of hippocampal synaptic plasticity. J Biol Chem 283:2631-2643.
53. Yoshii A, Constantine-Paton M. 2007. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat Neurosci 10:702-711.
54. Yoshii A, Constantine-Paton M. 2010. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70:304-322.
55. Zheng W, Wang H, Zeng Z, Lin J, Little PJ, Srivastava LK, Quirion R. 2012. The possible role of the Akt signaling pathway in schizophrenia. Brain Res 1470:145-158.